Hypersensitivity to Aurora Kinase Inhibitors in Cells Resistant against Platinum- Containing Anticancer Agents

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 14, 10 Issues, 2014


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 26th of 59 in Chemistry, Medicinal
  • 99th of 197 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.61

Hypersensitivity to Aurora Kinase Inhibitors in Cells Resistant against Platinum- Containing Anticancer Agents

Author(s): Masaki Akiyama, Hiroto Izumi, Ke-Yong Wang, Takahiro Yamaguchi, Akihiro Kuma, Noriaki Kitamura, Yoshikazu Harada, Ryoichi Oya, Koji Yamaguchi, Yoshiko Iwai and Kimitoshi Kohno

Affiliation: President Laboratory, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.

Abstract

The aurora kinases are serine/threonine kinases that are essential for mitosis and contribute to tumorigenesis. Therefore, aurora kinases hold promise for molecularly targeted therapy. In the present study, we demonstrated that aurora B kinase (AURKB) is overexpressed in both cisplatin- and oxaliplatin-resistant cells. Downregulation of AURKB sensitized cells to both cisplatin and oxaliplatin, but not to paclitaxel, 5-FU or hydrogen peroxide. Interestingly, we found that both cisplatin- and oxaliplatin-resistant cells were hypersensitive to the AURKB specific inhibitors, AZD1152 HQPA and ZM447439, suggesting that both cisplatin- and oxaliplatinresistant cells develop an addiction to AURKB. These data provide evidence that aurora kinase inhibitors can overcome both cisplatin and oxaliplatin resistance. Therefore, AURKB inhibitors could offer potential benefits if used after first-line platinum-based chemotherapy.

Keywords: Acquired drug resistance, addiction, AURKB, AURKB inhibitor, cisplatin, oxaliplatin.

Purchase Online Rights and Permissions

Article Details

Volume: 14
Issue Number: 7
First Page: 1042
Last Page: 1050
Page Count: 9
DOI: 10.2174/1871520614666140207154351
Advertisement


Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science